Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Cystic Fibrosis
In brief
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.
Key facts
- Study ID
- NCT07437105
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 128
- Starts
- 2026-02-25
- Expected to finish
- 2027-03-23
- Last updated by the study team
- 2026-03-31
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion - Tempe — Tempe, Arizona, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.